Terminal / Weight Loss

Liraglutide

Approved

aka Saxenda, Victoza

The original once-daily GLP-1. Semaglutide's older, shorter-acting predecessor.

Mechanism

A GLP-1 agonist you inject daily instead of weekly. Same idea as semaglutide, slows the stomach and raises satiety, just an older and shorter-acting molecule. It was the first GLP-1 to get the green light for chronic weight management.

Regulatory & Safety Status

Approved: Victoza for diabetes, Saxenda for obesity. Prescription drug, mostly superseded by the weekly options now.

Research

2026Journal of diabetes and metabolic disorders

Economic evaluation of tirzepatide, semaglutide, and liraglutide in the treatment of obese and overweight patients without diabetes: a short-term cost-effectiveness analysis in Iran

2026International journal of cardiology

GLP-1 receptor agonist therapy and incident atrial fibrillation in non-diabetic adults with obesity and chronic kidney disease: a propensity matched cohort study

2026Cardiovascular drugs and therapy

Epicardial Versus Circulating Adiponectin: An Unresolved Distinction in Liraglutide's Anti-Arrhythmic Mechanism

2026Cureus

Modern Obesity Treatment: Efficacy, Safety, and Future Directions of GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-Dependent Insulinotropic Polypeptide) Receptor Agonists

2024PubMed

Latest liraglutide research

Related Compounds

Weight Loss

Semaglutide

Approved

Approved GLP-1 agonist. The drug that kicked off the whole weight-loss gold rush.

Weight Loss

Tirzepatide

Approved

Approved dual agonist (GLP-1 and GIP). Currently the strongest thing you can get with a prescription.